… patients to erlotinib treatment, 40 patients to cabozantinib treatment, and 43 patients to erlotinib
… (erlotinib [n=38], cabozantinib [n=38], erlotinib plus cabozantinib [n=35]). Compared with …

… Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of non-small-…
tolerability of second-line erlotinib versus chemotherapy in patients with refractory NSCLC. …

… in patients receiving second-line erlotinib confirm that oral dosing with erlotinib offers patients
a … efficacy and reduced toxicity compared with conventional second-line chemotherapy. …

… evaluate the efficacy and safety of erlotinib as second-line therapy in NSCLC patients with
BM. … As erlotinib is approved for all patients regardless of EGFR mutation status in second line, …

… Total number of patients was 290. A group treated with chemotherapy … second line consisted
of 150 patients and a group treated with erlotinib in the second line consisted of 140 patients…

… Our results show that chemotherapy is more effective than erlotinib for second-line
treatment for previously treated patients with NSCLC who have wild-type EGFR tumours. …

… In this phase II trial we sought to evaluate the efficacy of erlotinib monotherapy in patients
with APC who had disease refractory to or ineligibility for gemcitabine-based therapy. …

… The small size and retrospective nature of this case series limits the findings of this analysis
of secondline erlotinib in NSCLC patients. In 50% of cases, investigators cited clinical …

… , erlotinib was effective in patients with wild-… erlotinib arms (P = .02).23 In a recent phase
3 trial, a comparison of docetaxel with erlotinib as second-line or third-line treatment in patients …

… erlotinib metabolism versus non-smoking patients, which reduces exposure. Therefore, an
increased erlotinib … and safety of 300 mg erlotinib (E300) as second-line therapy in current …